Impact of Valganciclovir Prophylaxis Duration on Cytomegalovirus Disease in High-Risk Donor Seropositive/Recipient Seronegative Heart Transplant Recipients

BACKGROUND: Few data support current guideline recommendations for 6 months over 3 months of antiviral prophylaxis for cytomegalovirus (CMV) disease prevention in donor seropositive/recipient seronegative (D+R-) heart transplant recipients (HTR). METHODS: We retrospectively assessed CMV disease and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Transpl Infect Dis
Autores principales: Imlay, Hannah, Carcoana, Allison O. Dumitriu, Fisher, Cynthia E., Wong, Beatrice, Rakita, Robert M., Fishbein, Daniel P., Limaye, Ajit P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284827/
https://ncbi.nlm.nih.gov/pubmed/32020736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tid.13255
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares